

Agreement Termination Notice of Dolutegravir Sublicense

To: General Counsel of Medicines Patent Pool of Geneva, Switzerland


Dear Sir/Madam,

We thank you very much for giving us the opportunity to participate in the battle against HIV. We have completed Process validation campaign and filed our DMF to WHO for approval. Anyhow after the re-evaluation of the real market situation of Dolutegravir, especially the numbers of approved vendors of dolutegravir drug substance, we found the supply safety of Dolutegravir is guaranteed and risk of shortage is gone. So we decide to stop further investment in Dolutegravir project after internal discussion. Hereby, we regret to inform you that we apply to terminate the License Agreement of Dolutegravir, effected as of 9th April 2018, signed between Zhejiang Langhua Pharmaceutical Co.,Ltd and THE MEDICINES PATENT POOL FOUNDATION.

We thank you very much for the kind support on this project and look forward to new collaboration in future.

Yours sincerely

Zhejiang Langhua Pharmaceutical Co.,Ltd

Signature: 

Name: Ji Shengbao

Titel: BD Director

Date: 28th Nov 2023